Rigel Pharmaceuticals (RIGL) Accounts Payables (2010 - 2026)

Rigel Pharmaceuticals' Accounts Payables history runs 17 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 13.45% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $4.5 million, a 13.45% increase from a year earlier, with the FY2025 full-year figure at $7.2 million, up 115.36% from the prior year.
• Accounts Payables retreated to $4.5 million in Q1 2026 per RIGL's latest filing, from $7.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $15.0 million in Q4 2022 and bottomed at $2.2 million in Q2 2022.
• The 5-year median for Accounts Payables is $5.2 million (2023), against an average of $5.9 million.
• Across the five-year window, Accounts Payables soared 295.26% in 2022 and plunged 57.37% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $15.0 million in 2022, then sank by 52.39% to $7.1 million in 2023, then sank by 53.25% to $3.3 million in 2024, then soared by 115.36% to $7.2 million in 2025, then plunged by 37.62% to $4.5 million in 2026.
• Per Business Quant, the three latest RIGL Accounts Payables figures stand at $4.5 million (Q1 2026), $7.2 million (Q4 2025), and $3.8 million (Q3 2025).